We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 362

Court of appeal upholds finding of infringement and only requires a "mere scintilla" of utility
  • Borden Ladner Gervais LLP
  • Canada
  • September 21 2016

The Federal Court of Appeal has dismissed Nova's appeal of an earlier finding that it had infringed Dow's patent relating to polyethylene used to make


Court of Appeal upholds construction of the promise distinguishing between the compounds and use claims
  • Borden Ladner Gervais LLP
  • Canada
  • September 21 2016

The Federal Court of Appeal dismissed an appeal from a decision prohibiting the Minister of Health from issuing a Notice of Compliance to Teva for


Trial judge acknowledges stare decisis and comity in relation to findings from the previous NOC proceedings
  • Borden Ladner Gervais LLP
  • Canada
  • September 21 2016

This was a patent infringement action against Apotex and Cobalt, relating to a combination of drospirenone and ethinylestradiol for an effective oral


Two panel Court of Appeal does not have subject-matter jurisdiction in this case to vary its three panel judgment
  • Borden Ladner Gervais LLP
  • Canada
  • September 21 2016

Pfizer moved for an order reconsidering and varying the judgment of the Court of Appeal's decision in 2016 FCA 161, summarized the week of June 13


Supreme Court Update - September 14, 2016
  • Borden Ladner Gervais LLP
  • Canada
  • September 14 2016

Sandoz Canada Inc. has discontinued its application for leave to appeal from the Federal Court of Appeal's decision, where the Court of Appeal


Intellectual Property Weekly Abstracts Bulletin
  • Borden Ladner Gervais LLP
  • Canada
  • September 28 2016

In a patent infringement action, the defendant brought a motion relating to read-ins of portions of the Examinations for discovery. In particular, the


Court ordered third party discovery of supplier of API
  • Borden Ladner Gervais LLP
  • Canada
  • February 7 2011

The case concerns an action for damages pursuant to s.8 of the NOC Regulations and a counterclaim for damages for patent infringement


Astrazeneca Canada Inc. v. Apotex Inc., 2015 FC 671
  • Borden Ladner Gervais LLP
  • Canada
  • July 7 2015

The parties moved under Rule 397 to modify the terms of the judgment in the proceeding, previously reported as 2015 FC 322 and summarized in our


Prohibition granted re the compound patent; dismissed re use and polymorph patents
  • Borden Ladner Gervais LLP
  • Canada
  • May 30 2014

This NOC proceeding deals with challenges to three patents, a compound patent, a use patent and a polymorph patent


Patent is not found to be a selection patent, and thus was anticipated and obvious
  • Borden Ladner Gervais LLP
  • Canada
  • November 23 2015

The Federal Court has dismissed an application for prohibition to prevent the Minister of Health from issuing an NOC to Mylan for cinacalcet